TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06072859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Humidified Forest Oils
Description: 60mls Limonene in 200mls water humidified with a diffuser.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Humidified Forest Oils
Description: 60mls Limonene in 200mls water humidified with a diffuser.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality using Surface Pro and headphones
Description: Surface Pro has a looped visual that can be manipulated by the participant to simulate walking on a forest path or through a forest visual. This is paired with headphones to experience ambient forest sounds.
Study: NCT04839991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB307
Description: Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB307
Description: Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
Study: NCT06082869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protegera™ toothpaste (NaF)
Description: Plaque Reduction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest™ Cavity Protection toothpaste (NaF)
Description: Plaque Reduction
Study: NCT05181904

Intervention type: OTHER
Intervention: Gastric ultrasound
Description: Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
Study: NCT05781763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: 2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Continuing with exercise as usual during 12 months
Study: NCT04904965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 1
Description: Propofol 2.0 mg/kg/hr per 10 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 2
Description: Propofol 4.0 mg/kg/hr per 10 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 3
Description: Propofol 6.0 mg/kg/hr per 10 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 4
Description: Propofol 8.0 mg/kg/hr per 10 min
Study: NCT06184737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSIPsmarter
Description: iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education (PE)
Description: The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
Study: NCT00819975

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Study: NCT05548816

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
Study: NCT05486936

Intervention type: RADIATION
Intervention: hypofractionated radiation
Description: Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
Study: NCT04878393

Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT06513533

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: 1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
Study: NCT06361004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Description: The DBS lead is stereotactically introduced into the target in the brain (GPi, amGPi, pvGPi, Cm-Spv-Voi, Cm-Voi, NA-ALIC, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
Study: NCT00819975

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alphalact-Albumin
Study: NCT05137470

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study: NCT06219226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide mouthwash
Description: This one rinsing will last 2x15 seconds(2x12,5ml).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: This one rinsing will last 2x15 seconds(2x12,5ml).
Study: NCT05079763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial cellulose-monolaurin hydrogel
Description: Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
Study: NCT05541484

Intervention type: DRUG
Group type: OTHER
Intervention: SGLT2 inhibitor
Description: See above.

Intervention type: DRUG
Group type: OTHER
Intervention: SGLT2 inhibitor
Description: See above.

Intervention type: DEVICE
Group type: OTHER
Intervention: Biosense Breath Ketone Analyzer
Description: The hand-held device tests ketones in exhaled breath

Intervention type: DEVICE
Group type: OTHER
Intervention: Biosense Breath Ketone Analyzer
Description: The hand-held device tests ketones in exhaled breath
Study: NCT04781348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma plus fat grafting
Description: The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma plus fat grafting
Description: The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
Study: NCT06142123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-D Ankle Mobility Exercises(A)
Description: The techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~1. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the prone position according to the resistance of therapist.~2. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the prone position according to the resistance of therapist.~3. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the crook-lying position according to the resistance of therapist.~4. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the crook-lying position according to the resistance of therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Heel Drop Training(B)
Description: : Group B will be treated with Eccentric Heel Drop Training. It will comprise of following exercises (14).~1. Eccentric loading exercises of calf muscles.~2. Conventional physiotherapy treatment including Ultrasound Plantar fascia stretching Calf muscle stretching Intrinsic muscles strengthening
Study: NCT06482775

Intervention type: DRUG
Intervention: dexmedetomidine
Description: The dosing and administration will be implemented according to an algorithm based on pain scoring results
Study: NCT06364956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with two predefined dose groups of palbociclib
Description: Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
Description: After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
Study: NCT06323694

Intervention type: BEHAVIORAL
Intervention: quality of life
Description: data collection through questionnaire and interview

Intervention type: BEHAVIORAL
Intervention: quality of life
Description: data collection through questionnaire and interview
Study: NCT06014294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baduanjin
Description: As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Workshop
Description: Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
Study: NCT04711759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard oxygen therapy
Description: Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard oxygen therapy
Description: Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
Study: NCT06281405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Short-course radiotherapy: 25Gy/5Fx
Study: NCT05649644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Trunk Block (SeTB)
Description: Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. After local anesthetic (LA) infiltration (1-2 ml lidocaine 1%), the nerve block needle will be inserted and placed within the interscalene groove. Then, a 7 ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. After that, the tip will be redirected lateral to the middle trunk. A further 8 ml of the LA mixture will be injected after which the nerve block needle will be completely withdrawn. The transducer will then be manipulated to a sub-omohyoid position. After LA infiltration, the nerve block needle is inserted in-plane until the needle tip is positioned close to and lateral to (9-12 o'clock position) the inferior trunk. A 10 ml of the LA mixture is injected in small aliquots and the needle will be removed after the injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block (SC BPB)
Description: Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. Patient will receive a subcutaneous infiltration with 1-2 ml of 0.9% normal saline (NS) at the superior and middle trunk level after which the needle will be completely withdrawn. Then, a local anesthetic (LA) infiltration (1-2 ml lidocaine 1%) will then be performed at the supraclavicular fossa and the nerve block will be inserted in-plane to place the needle tip at the corner pocket. After that, 15-ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. Once completed, the needle tip is gently withdrawn and redirected into the cluster formed by the divisions of brachial plexus. Then, the remaining 10-ml of the same LA mixture will be injected in small aliquots and the needle will be removed after the injection.
Study: NCT05699317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal stimuli
Description: Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied.
Study: NCT05010993

Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test
Description: Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)

Intervention type: DIAGNOSTIC_TEST
Intervention: Purdue Pegboard Test
Description: Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)

Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: Each person will be tested by the Box and Block Test (3 attempts per subtest)
Study: NCT05775302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM of Gastrocnemius + Conventional therapy
Description: The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM of AchillesTendon + Conventional Therapy
Description: Participants will receive a maximum of 60 seconds\<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
Study: NCT06017492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video assisted discharge teaching
Description: Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
Study: NCT04604743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention, TBN
Description: The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
Study: NCT06182930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.
Description: They will receive routine home health care follow-up.
Study: NCT04997824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-based atrial fibrillation catheter ablation
Description: 1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. AI-guided prediction for poor responder of AFCA in the outpatient clinic~3. Sharing information on the AI prediction with the patient and family member~4. AFCA after consent to the procedure~5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~6. Monitoring esophageal temperature~7. Evaluation of Procedure and ablation time, and complication afer procedure~8. Post-procedure rhythm follow-up is carried out according to the study design above.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: 1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. Decision for AFCA based on clinical guidelines and the experience of the attending physician~3. AFCA after consent to the procedure~4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~5. Monitoring esophageal temperature~6. Evaluation of Procedure and ablation time, and complication afer procedure
Study: NCT05662735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh repair
Description: Augmentation of hiatal hernia repair with TiMESH® reinforcement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture repair
Description: Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture repair
Description: Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures